NRG Oncology/RTOG 0848: Results after adjuvant chemotherapy +/- chemoradiation for patients with resected periampullary pancreatic adenocarcinoma (PA).

A. Abrams, Ross; Winter, Kathryn; A. Goodman, Karyn; Regine, W.; Safran, Howard; C. Berger, Adam; Guha, Chandan; A. Kachnic, Lisa; T. Gillin, Michael; A. Seaward, Samantha; J. Wu, Abraham; Wu, Jennifer; Aljumaily, Raid; A. DiPetrillo, Thomas; Geva, Ravit; R. Anné, Pramila; Yannucci, Jennifer; Liles, Darla; Moughan, Jennifer; H. Crane, Christopher

doi:10.1200/jco.2024.42.16_suppl.4005

Public

NRG Oncology/RTOG 0848: Results after adjuvant chemotherapy +/- chemoradiation for patients with resected periampullary pancreatic adenocarcinoma (PA).

Published in Journal of Clinical Oncology • Jun 1, 2024

Authors:

Ross A. Abrams

Kathryn Winter

Karyn A. Goodman

Abstract

4005 Background: If 5FU/Capecitabine sensitized radiotherapy (RT) is beneficial in the adjuvant (adj) management of PA after adj chemotherapy (chemo) is controversial. NRG/RTOG 0848 was designed to address this issue. Methods: This was a 2 step NCTN randomized (rndmzd) trial. Step 1 rndmzd patients ...

Subject

Medicine

Adenocarcinoma

Internal medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!